Therefore, when SOR is combined with the drugs metabolized by UGT1A9 in HCC patients, physicians and pharmacists should pay special attention to drug interactions mediated by this inhibitory effect. The gene discussed is UGT1A9; the disease is hepatocellular carcinoma.